Research graph
References from Prolonged Active SARS-CoV-2 Infection in a Patient With Chronic Lymphocytic Leukemia on Venetoclax. Local targets link to admitted publications; unresolved targets remain external evidence.
Treatment of chronic or relapsing COVID-19 in immunodeficiency
10.1016/j.jaci.2021.10.031 · 2022 · External reference
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: a narrative review
10.1111/tid.14301 · 2024 · External reference
Persistent COVID-19 in immunocompromised patients-Israeli society of infectious diseases consensus statement on diagnosis and management
10.1016/j.cmi.2024.04.009 · 2024 · External reference
Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients
10.1093/cid/ciad181 · 2023 · External reference
Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside
10.1097/qco.0000000000000841 · 2022 · External reference
Case report: long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: the emerging therapeutic role of casirivimab/imdevimab
10.3389/fonc.2022.945060 · 2022 · External reference
Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies
10.1002/ijc.34988 · 2024 · External reference
Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects
10.1016/j.jiac.2023.10.022 · 2024 · External reference
Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-CoV-2 infection: defining a treatment pathway
10.3389/fimmu.2022.911339 · 2022 · External reference
Early combination therapy of COVID-19 in high-risk patients
10.1007/s15010-023-02125-5 · 2024 · External reference
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy
10.1186/s12941-021-00491-2 · 2021 · External reference
High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge
10.1111/tid.14055 · 2023 · External reference
Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies
10.1002/ijc.34988 · ExternalCitation · doi-reference
Early combination therapy of COVID-19 in high-risk patients
10.1007/s15010-023-02125-5 · ExternalCitation · doi-reference
Persistent COVID-19 in immunocompromised patients-Israeli society of infectious diseases consensus statement on diagnosis and management
10.1016/j.cmi.2024.04.009 · ExternalCitation · doi-reference
Treatment of chronic or relapsing COVID-19 in immunodeficiency
10.1016/j.jaci.2021.10.031 · ExternalCitation · doi-reference
Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects
10.1016/j.jiac.2023.10.022 · ExternalCitation · doi-reference
Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients
10.1093/cid/ciad181 · ExternalCitation · doi-reference
Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside
10.1097/qco.0000000000000841 · ExternalCitation · doi-reference
High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge
10.1111/tid.14055 · ExternalCitation · doi-reference
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: a narrative review
10.1111/tid.14301 · ExternalCitation · doi-reference
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy
10.1186/s12941-021-00491-2 · ExternalCitation · doi-reference
Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-CoV-2 infection: defining a treatment pathway
10.3389/fimmu.2022.911339 · ExternalCitation · doi-reference
Case report: long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: the emerging therapeutic role of casirivimab/imdevimab
10.3389/fonc.2022.945060 · ExternalCitation · doi-reference
